Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine plus Imatinib in Resistant GIST
NCT00455559Phase 2Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Aug 2006
- Primary completion
- Nov 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of perifosine in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoints: Efficacy and Safety. Started Aug 2006; status: completed.
02
Drugs
perifosine
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00455559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455559.